key: cord-0703071-qmy8jw08 authors: Andrianto, A.; Al-Farabi, M. J.; Nugraha, R. A.; Marsudi, B. A.; Azmi, Y. title: Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis date: 2021-01-26 journal: nan DOI: 10.1101/2021.01.24.21250389 sha: 59444edb1725d57107fea71ac46ac19c884b7cec doc_id: 703071 cord_uid: qmy8jw08 Background. Several studies have reported that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect endothelial cells, and endothelial dysfunction is often found in severe cases of coronavirus disease 2019 (COVID-19). To better understand the pathological mechanisms underlying endothelial dysfunction in COVID-19-associated coagulopathy, we conducted a systematic review and meta-analysis to assess biomarkers of endothelial cells in patients with COVID-19. Methods. A literature search was conducted on online databases for observational studies evaluating biomarkers of endothelial dysfunction and composite poor outcomes in COVID-19 patients. Results. A total of 1187 patients from 17 studies were included in this analysis. The estimated pooled means for von Willebrand Factor (VWF) antigen levels in COVID-19 patients was higher compared to healthy control (306.42 [95% confidence interval (CI) 291.37-321.48], p<0.001; I2:86%), with the highest VWF antigen levels was found in deceased COVID-19 patients (448.57 [95% CI 407.20-489.93], p<0.001; I2:0%). Meta-analysis showed that higher plasma levels of VWF antigen, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 antigen (PAI-1) antigen, and soluble thrombomodulin (sTM) were associated with composite poor outcome in COVID-19 patients ([standardized mean difference (SMD) 0.74 [0.33-1.16], p<0.001; I2:80.4%], [SMD 0.55 [0.19-0.92], p=0.003; I2:6.4%], [SMD 0.33 [0.04-0.62], p=0.025; I2:7.9%], and [SMD 0.55 [0.10-0.99], p=0.015; I2:23.6%], respectively). Conclusion. The estimated pooled means shows increased levels of VWF antigen in COVID-19 patients. Several biomarkers of endothelial dysfunction, including VFW antigen, t-PA, PAI-1, and sTM, are significantly associated with increased composite poor outcome in patients with COVID-19. Keywords: Endothelial dysfunction, von Willebrand Factor, tissue-type plasminogen activator, plasminogen activator inhibitor-1, thrombomodulin, COVID-19 PROSPERO registration number: CRD42021228821 Although initially recognized as a disease affecting the respiratory system, the coronavirus 75 disease 2019 (COVID-19) often manifests as cardiovascular complications such as myocarditis, 76 myocardial injuries, arrhythmias, and venous thromboembolism events (VTE) [1] . There are 77 several possible mechanisms for these phenomena, one of which may be an unrestrained and 78 unbalanced innate immune response, which in turn negates effective adaptive immunity, 79 supporting the progression of COVID-19. Frequent laboratory abnormalities in patients with 80 unfavorable progression of COVID-19 include abnormal cytokine profiles, which led to the 81 initial presumption that the immune response to severe acute respiratory syndrome 82 coronavirus 2 (SARS-CoV-2) infection involved a cytokine storm [2] . However, recent evidence 83 suggests that increased inflammatory cytokines including interleukin-6 (IL-6) in patients with 84 severe and critical COVID-19 are significantly lower compared to patients with sepsis and 85 acute respiratory distress syndrome (ARDS) not associated with COVID-19, thus doubting the 86 outcomes. The biomarkers of endothelial dysfunction analyzed in this study were von 121 Willebrand Factor (VWF) antigen, tissue-type plasminogen activator (t-PA), plasminogen 122 activator inhibitor-1 antigen (PAI-1), and soluble thrombomodulin (sTM). The primary 123 endpoint was composite poor outcomes consisting of ICU admission, severe illness, worsening 124 of the respiratory status, the need for mechanical ventilation, and mortality. Moreover, if the 125 included studies reported the data using median and quartile values, we used the formula 126 developed by Wan et al. to estimate mean and standard deviation [7] . Disease severity was 127 defined based on the WHO R&D Blueprint on COVID-19 [8] . 128 The quality and risk of bias assessment of included studies were conducted using the 130 analysis to test the robustness of the pooled effect estimates for VWF antigen levels by 144 excluding each study sequentially and rerunning the meta-analysis. The funnel-plot analysis 145 was used to assess the symmetrical distribution of effect sizes, and the regression-based Egger 146 test was performed to assess publication bias on continuous endpoints. 147 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (Figure 3) . 171 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250389 doi: medRxiv preprint We found substantial heterogeneity for VWF antigen analysis (I 2 :80.4%) and low 172 heterogeneity for t-PA, PAI-1 antigen, and sTM analysis (I 2 :6.4%, I 2 :7.9%, and I 2 :23.6%, 173 respectively). However, subgroup analyses to evaluate potential sources of heterogeneity of 174 VWF levels were not performed due to the small amount of primary data included in the group 175 analysis. The sensitivity analysis of VWF levels after excluding two studies [19, 24] Harbord's test for other biomarkers and composite poor outcome also showed no significant 185 result of small-study effects. 186 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250389 doi: medRxiv preprint reducing nitric oxide (NO) production [4] . Porcine animal models have recently revealed a 211 vicious self-perpetuating pathway, whereby ROS production increases expression of ET-1, 212 which results in further ROS production. Increased vWF expression has also been shown to 213 increase ET-1 expression, alternatively, knockdown of vWF expression has been shown to 214 decrease AngII-induced-ET-1 production [30]. Decreased ACE2 levels can also promote 215 prothrombotic signaling by limiting the degradation of des-Arg9 bradykinin, thereby 216 increasing the activated bradykinin receptors [31] . (e.g., PAI-1) and procoagulants (e.g., tissue factor) over the expression of profibrinolytic 228 mediators (e.g., t-PA) and anticoagulants (e.g., heparin-like molecules and thrombomodulin) 229 [28]. Taken together, these mechanisms contribute to massive platelet binding and formation 230 of fibrin, leading to deposition of blood clots in the microvasculature and systemic thrombosis 231 [2] . However, viral RNA of SARS-CoV-2 is rarely detected in the blood [34] , which suggests that 232 rather than direct viral infection of endothelial cells, additional host-dependence factors may 233 contribute to systemic endothelial dysfunction and vasculopathy in COVID-19. 234 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in One of the 17 studies included in this meta-analysis was a preprint article. Nevertheless, a 296 thorough assessment has been made to make sure that only sound studies are included. Most 297 of the included studies had a retrospective observational design, and the data were not 298 sufficiently matched or adjusted for confounders. Moreover, our primary endpoints of 299 composite poor outcomes vary widely from ICU admission, severe illness, worsening of the 300 respiratory status, the need for mechanical ventilation to death. Therefore, the results must 301 be cautiously interpreted. 302 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250389 doi: medRxiv preprint There was an increase in the VWF antigen levels in COVID-19 patients, and the highest levels 304 of VWF antigen were found in deceased COVID-19 patients. Biomarkers of endothelial 305 dysfunction, including VWF antigen, t-PA, PAI-1 antigen, and sTM, are significantly associated 306 with an increased composite poor outcome in patients with COVID-19. 307 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250389 doi: medRxiv preprint 1 Cugno, 2020 **** * *** 2 Fan, 2020 *** * ** 3 Goshua, 2020 **** ** *** 4 Helms, 2020 *** ** ** 5 Henry, 2020 **** ** *** 6 Hoechter, 2020 *** ** ** 7 Ladikou, 2020 *** ** ** 8 Mancini, 2020 *** * *** 9 Morici, 2020 *** * ** 10 Nougier, 2020 **** ** *** 11 Panigada, 2020 *** * ** 12 Pine, 2020 *** ** *** 13 Ranucci, 2020 *** ** *** 14 Rauch, 2020 **** * ** 15 Rovas, 2020 **** ** *** 16 Sweeney, 2020 **** * ** 17 Taus, 2020 **** ** ** 525 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250389 doi: medRxiv preprint Endothelial 325 dysfunction in COVID-19: a position paper of the ESC Working Group for 326 Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular 327 Immunity, endothelial 329 injury and complement-induced coagulopathy in COVID-19 Cytokine 332 elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, 333 and comparison with other inflammatory syndromes Endothelial dysfunction 335 in COVID-19: Current findings and therapeutic implications Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients 396 compared to non-COVID-19 ARDS patients Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in 400 Willebrand factor axis in COVID-19 patients Factor and ADAMTS-13 in the Pathogenesis of Thrombi in SARS-CoV-2 Infection: Time 406 to Rethink Gene 421 silencing of endothelial von Willebrand Factor attenuates angiotensin II SARS-CoV-2 424 and ACE2: The biology and clinical data settling the ARB and ACEI controversy COVID-19: the vasculature unleashed Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular 430 compartments in severe COVID-19 Virological assessment of hospitalized patients with COVID-2019 plasma von Willebrand factor levels in patients with active ulcerative colitis reflect 468 endothelial perturbation due to systemic inflammation VWF) and VWF propeptide profiles in patients 472 with DIC and related diseases ADAMTS-13, von Willebrand factor and related parameters in severe 475 sepsis and septic shock Willebrand factor propeptide to ADAMTS13 is associated with severity of sepsis COVID-19) OR (coronavirus disease 2019) OR (COVID 19) OR COVID19 OR "2019 novel coronavirus" OR 2019nCoV OR (2019 nCoV) OR "new coronavirus" OR (Wuhan AND coronavirus) OR (SARS CoV-2) OR ICAM-1 OR VCAM-1 OR E-Selectin OR P-Selectin OR PAI OR von Willebrand OR VWF OR thrombomodulin OR CD40 ligan).ti. ab #1 AND OR (COVID-19) OR COVID19 OR "new coronavirus" OR "novel coronavirus" OR (SARS CoV-2) OR (Wuhan AND coronavirus) OR (COVID 19) OR (2019 nCoV) OR (SARS-CoV-2) OR (coronavirus disease